Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
By Helena Smolak AstraZeneca said its experimental drug for non-small cell lung cancer, jointly developed with Japan s Daiichi Sankyo, showed improvement in progression-free survival in its.
Datopotamab Deruxtecan Improves Survival in Advanced Lung Cancer Trial miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Highlevel overall survival OS results from the TROPIONLung01 Phase III trial which previously met the dual primary endpoint of progressionfree survival PFS numerically favoured datopotamab deruxtecan DatoDXd compared to docetaxel in the overall trial population of patients with locally advanced or metastatic nonsmall cell lung cancer NSCLC treated with at least one prior line of therapy.
AstraZeneca continues its ambition to redefine cancer care by unveiling new data at the American Society of Clinical Oncology annual meeting from May 31 to June 4, 2024. More than 100 abstracts will.